drugset
drugset / Trial / NCT04733521

A Phase 1/2 Study of SC-43 in Combination With Cisplatin

NCT04733521 ↗

Phase 1/2 Unknown 100 enrolled RaND Biosciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma

Timeline

Start
2021-05-01
Primary completion
2023-09-30
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SC-43 Small molecule 50 mg Oral
Subject SC-43 Small molecule 100 mg Oral
Subject SC-43 Small molecule 150 mg Oral
Background Cisplatin Other / unclassified 75 mg/m2 —

Indications

biliary tract cancer non-small cell lung carcinoma